Author:
Cai Xiaojie,Gao Jie,Liu Yanfang,Wang Ming,Ma Qiulian,Gong Aihua,Wang Dongqing,Zhu Haitao
Abstract
Pancreatic carcinoma is the fourth leading cause of cancer death in the word wild. Although the advance in treatment this disease, the 5-years survival rate is still rather low. In the recent year, many new therapy and treatment avenues have been developed for pancreatic cancer. In this chapter, we mainly focus on the following aspect: 1) the treatment modality in pancreatic cancer, including chemotherapy, radiotherapy, and immunotherapy; 2) the mechanism of pancreatic cancer treatment resistance, especially in cancer stem cells and tumor microenvironment; 3) the diagnosis tools in pancreatic cancer, including serum markers, imaging methods and endoscopic ultrasonography. Novel molecular probes based on the nanotechnology in the diagnosis of pancreatic cancer are also discussed.
Reference94 articles.
1. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer research. 2014;74(11):2913-292
2. American Cancer Society. Cancer Facts and Figures 2018
3. National Comprehensive Cancer Network (NCCN) guidelines 2018
4. Terumi Kamisawa, Laura D. Wood, Takao Itoi, Kyoichi Takaori. Pancreatic cancer. The Lancet. 2016;388(10039):73-85
5. Ryan DP, Hong TS, Bardeesy N. Pancreatic adenocarcinoma. N Engl J Med. 2014;371(11):1039-1049